1. Bowling EA, Wang JH, Gong F, et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer [published online ahead of print, 2021 Jan 13]. Cell. 2021;S0092-8674(20)31753-0. doi:10.1016/j.cell.2020.12.0312. Triggering tumor antiviral immune response in triple negative breast cancer. Retrieved Jan. 15, 2021, from https://www.bcm.edu/news/triggering-antiviral-immune-response-in-certain-breast-cancers3. Challenor, S. and D. Tucker, SARS-CoV-2-induced remission of Hodgkin lymphoma. British Journal of Haematology. n/a(n/a).